ADB-PINACA

ADB-PINACA is a cannabinoid designer drug that is an ingredient in some synthetic cannabis products. It is a potent agonist of the CB1 receptor and CB2 receptor with EC50 values of 0.52 nM and 0.88 nM respectively.[1][2] Like MDMB-FUBINACA, this compound contains an amino acid residue of tert-leucine.

ADB-PINACA
Legal status
Legal status
Identifiers
IUPAC name
  • N-(1-Amino-3,3-dimethyl-1-oxo-2-butanyl)-1-pentyl-1H-indazole-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC19H28N4O2
Molar mass344.459 g·mol−1
3D model (JSmol)
SMILES
  • CCCCCN1C2=CC=CC=C2C(=N1)C(=O)NC(C(=O)N)C(C)(C)C
InChI
  • InChI=1S/C19H28N4O2/c1-5-6-9-12-23-14-11-8-7-10-13(14)15(22-23)18(25)21-16(17(20)24)19(2,3)4/h7-8,10-11,16H,5-6,9,12H2,1-4H3,(H2,20,24)(H,21,25)
  • Key:FWTARAXQGJRQKN-UHFFFAOYSA-N

Side effects

ADB-PINACA has been linked to multiple hospitalizations and deaths due to its use.[3][4][5]

Metabolism

Nineteen ADB-PINACA major metabolites were identified in several incubations with cryopreserved human hepatocytes. Major metabolic reactions included pentyl hydroxylation, hydroxylation followed by oxidation (ketone formation), and glucuronidation.[6]

Legality

ADB-PINACA is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.[7]

In the United States, it is a Schedule I controlled substance.[8]

As of October 2015 ADB-PINACA is a controlled substance in China.[9]

See also

References
  1. Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA". ACS Chemical Neuroscience. 6 (9): 1546–59. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
  2. "ADB-PINACA". Forendex. Archived from the original on 2014-07-14. Retrieved 2014-07-09.
  3. "CDC: 221 sickened by synthetic pot in Colorado". USA Today. December 12, 2013.
  4. Schwartz MD, Trecki J, Edison LA, Steck AR, Arnold JK, Gerona RR (May 2015). "A Common Source Outbreak of Severe Delirium Associated with Exposure to the Novel Synthetic Cannabinoid ADB-PINACA". The Journal of Emergency Medicine. 48 (5): 573–80. doi:10.1016/j.jemermed.2014.12.038. PMID 25726258.
  5. Trecki J, Gerona RR, Schwartz MD (July 2015). "Synthetic Cannabinoid-Related Illnesses and Deaths". The New England Journal of Medicine. 373 (2): 103–7. doi:10.1056/NEJMp1505328. PMID 26154784.
  6. Carlier J, Diao X, Scheidweiler KB, Huestis MA (May 2017). "Distinguishing Intake of New Synthetic Cannabinoids ADB-PINACA and 5F-ADB-PINACA with Human Hepatocyte Metabolites and High-Resolution Mass Spectrometry". Clinical Chemistry. 63 (5): 1008–1021. doi:10.1373/clinchem.2016.267575. PMID 28302730.
  7. "CNB NEWS RELEASE". Central Narcotics Bureau (CNB). 30 April 2015. Archived from the original on 15 July 2015. Retrieved 24 July 2015.
  8. Drug Enforcement Administration, Department of Justice (February 2014). "Schedules of controlled substances: temporary placement of four synthetic cannabinoids into Schedule I. Final order". Federal Register. 79 (27): 7577–82. PMID 24605391.
  9. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.